A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease

April 15, 2019
https://clinicaltrials.gov/ct2/show/NCT03710707
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD
Parkinson's disease, LRRK2, parkinson's
Open
(248)661-6540